Executive Summary

GeriatRx is a Black-owned, pharmacist-led clinical company focused on one thing: helping older adults age safely by reducing medication overload. We offer concierge deprescribing services, precision medicine through pharmacogenomics (PGx), and compassionate care coordination to families, facilities, and health systems.

We’re not a product-based business, our value lies in our expertise, relationships, and outcomes. Over the next few years, we plan to scale nationally through franchise partnerships and globally through training, policy work, and system-level change.

We’re building the future of aging — where fewer meds, more clarity, and better care are the norm.

📈 Market Analysis

<aside>

🎯 Our Target Market

Consumers (B2C)

• Adults aged 40–75 caring for aging loved ones
• High-income professionals (lawyers, physicians, business leaders)
• People who value convenience, privacy, and expertise

Organizations (B2B)

• Independent & assisted living communities
• Home care agencies
• Concierge medical practices
• Self-insured employers
• Payer groups like the VA, state health plans, Medicare Advantage </aside>

<aside>

🧠 Industry Trends

• The U.S. home care industry is valued at $130+ billion
• 50M+ adults are currently aged 65+, expected to double by 2060
• Polypharmacy, fall risks, and unnecessary hospitalizations are on the rise
• CMS and insurers are rewarding outcomes-based care, opening doors for GeriatRx </aside>

<aside>

🥇 How We Stand Out

While others may offer medication reviews, we go deeper:

Our advantage:

We combine clinical credibility with a personalized, high-touch approach that’s scalable. We build trust through cultural competency, storytelling, and strong partnerships — and we’re laser-focused on deprescribing as our niche.

</aside>

🎯 Strategic Objectives

<aside>

Short-Term (0–12 Months)

• Expand direct-to-consumer services and facility contracts
• Increase enrollment in our Deprescribing Accelerator program
• Grow PGx testing and care plan offerings </aside>

🛠 Action Plans

<aside>

Medium-Term (1–3 Years)

• Launch franchise pilot sites in new regions
• Grow team to 50+ professionals
• Partner with senior living communities to reduce medication errors and improve resident outcomes </aside>

<aside>

Long-Term (5+ Years)

• Scale nationally through franchising and licensed care teams
• Train thousands through our Accelerator and continuing education
• Shape public health policy and national formularies around aging and medications </aside>

<aside>

• Build out our franchise model with regional licensing opportunities
• Create SOPs and internal systems to support national scaling
• Deepen partnerships with payers like the VA and state Medicaid programs
• Ensure all services include pharmacogenomic testing and personalized plans

Already in motion:

✅ 30% drop in med errors at a facility within 6 months of partnership

✅ PGx success stories with quick therapeutic improvements

✅ Increasing demand for education/training services

</aside>

<aside>

💰 Financial Overview

Our revenue comes from four main streams:

• Concierge consultations & care coordination (B2C)
• Facility & agency contracts (B2B)
• PGx testing and interpretation
• Education: Accelerator program, workshops, CE speaking engagements

Our model is high-touch, low-volume — prioritizing quality, trust, and intentional growth. Franchising and training allow us to scale without sacrificing care.

</aside>

🛡 Risk Management

<aside>

Potential Challenges

• Public unfamiliarity with deprescribing
• Hesitancy from providers not used to working with clinical pharmacists
• Risks of scaling too fast without infrastructure </aside>